206 related articles for article (PubMed ID: 37604683)
41. Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
Rodríguez-García A; Linares M; Morales ML; Allain-Maillet S; Mennesson N; Sanchez R; Alonso R; Leivas A; Pérez-Rivilla A; Bigot-Corbel E; Hermouet S; Martínez-López J
Front Immunol; 2021; 12():797209. PubMed ID: 35087522
[TBL] [Abstract][Full Text] [Related]
42. Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study.
Peng W; den Boer MA; Tamara S; Mokiem NJ; van der Lans SPA; Bondt A; Schulte D; Haas PJ; Minnema MC; Rooijakkers SHM; van Zuilen AD; Heck AJR; Snijder J
J Proteome Res; 2023 Sep; 22(9):3022-3028. PubMed ID: 37499263
[TBL] [Abstract][Full Text] [Related]
43. Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.
Espiño M; Medina S; Blanchard MJ; Villar LM
Br J Haematol; 2014 Mar; 164(5):752-5. PubMed ID: 24261626
[No Abstract] [Full Text] [Related]
44. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).
Papanikolaou X; Rosenthal A; Dhodapkar M; Epstein J; Khan R; van Rhee F; Jethava Y; Waheed S; Zangari M; Hoering A; Crowley J; Alapat D; Davies F; Morgan G; Barlogie B
Blood Cancer J; 2016 Mar; 6(3):e410. PubMed ID: 27015287
[No Abstract] [Full Text] [Related]
45. Monoclonal and biclonal immunoglobulin-producing disorders.
Osterborg A; Mellstedt H
Eur J Haematol Suppl; 1989; 51():11-8. PubMed ID: 2697582
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal gammopathy and multiple myeloma in the elderly.
Kyle RA
Baillieres Clin Haematol; 1987 Jun; 1(2):533-57. PubMed ID: 3322448
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
48. [Usefulness of free light chain measurement in monoclonal gammopathy, other haematological malignancies and autoimmune diseases].
Verebi C; Talbot A; Gendron N; Hurtado-Nedelec M
Ann Biol Clin (Paris); 2019 Aug; 77(4):397-406. PubMed ID: 31418701
[TBL] [Abstract][Full Text] [Related]
49. [Monoclonal gammopathies of undetermined significance called "MGUS"].
Clément F
Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
[TBL] [Abstract][Full Text] [Related]
50. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
51. Importance of quantitative histology of bone changes in monoclonal gammopathy.
Bataille R; Chappard D; Alexandre C; Dessauw P; Sany J
Br J Cancer; 1986 Jun; 53(6):805-10. PubMed ID: 3718833
[TBL] [Abstract][Full Text] [Related]
52. [Benign monoclonal gammopathies].
Sibilia J; Fermand JP
Rev Prat; 1993 Feb; 43(3):289-92. PubMed ID: 8502957
[TBL] [Abstract][Full Text] [Related]
53. Current concepts on monoclonal gammopathies.
Kyle RA
Aust N Z J Med; 1992 Jun; 22(3):291-302. PubMed ID: 1497556
[TBL] [Abstract][Full Text] [Related]
54. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
55. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
56. Establishing Monoclonal Gammopathy of Undetermined Significance as an Independent Pre-Disease State of Multiple Myeloma Using Raman Spectroscopy, Dynamical Network Biomarker Theory, and Energy Landscape Analysis.
Yonezawa S; Haruki T; Koizumi K; Taketani A; Oshima Y; Oku M; Wada A; Sato T; Masuda N; Tahara J; Fujisawa N; Koshiyama S; Kadowaki M; Kitajima I; Saito S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338848
[TBL] [Abstract][Full Text] [Related]
57. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous manifestations of monoclonal gammopathy.
Claveau JS; Wetter DA; Kumar S
Blood Cancer J; 2022 Apr; 12(4):58. PubMed ID: 35411042
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal gammopathy of undetermined significance in medical hospital admissions - a new strategy for screening?
Turesson I
Br J Haematol; 2020 Jun; 189(6):1010-1011. PubMed ID: 32072614
[No Abstract] [Full Text] [Related]
60. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
